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Chloroquine (CQ) has been the mainstay of malaria treatment for more than 60 years. However, the emergence and spread of
CQ resistance now restrict its use to only a few areas where malaria is endemic. The aim of the present study was to investigate
whether a novel combination of a CQ-like moiety and an imipramine-like pharmacophore can reverse CQ resistance ex vivo.
Between March to October 2011 and January to September 2013, two “reversed chloroquine” (RCQ) compounds (PL69 and
PL106) were tested against multidrug-resistant field isolates of Plasmodium falciparum (n 41) and Plasmodium vivax (n 45)
in Papua, Indonesia, using a modified ex vivo schizont maturation assay. The RCQ compounds showed high efficacy against
both CQ-resistant P. falciparum and P. vivax field isolates. For P. falciparum, the median 50% inhibitory concentrations (IC50s)
were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P< 0.001 and P 0.036, respectively).
The corresponding values for P. vivax were 19.0, 60.0, and 60.9 nM (P< 0.001 and P 0.018, respectively). There was a signifi-
cant correlation between IC50s of CQ and PL69 (Spearman’s rank correlation coefficient [rs] 0.727, P< 0.001) and PL106 (rs
0.830, P< 0.001) in P. vivax but not in P. falciparum. Both RCQs were equally active against the ring and trophozoite stages of
P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and
172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM). RCQ compounds have enhanced ex vivo activity against
CQ-resistant clinical isolates of P. falciparum and P. vivax, suggesting the potential use of reversal agents in antimalarial drug
development. Interspecies differences in RCQ compound activity may indicate differences in CQ pharmacokinetics between the
two Plasmodium species.
Malaria remains one of themost important infectious diseasesin the world (1). A key component of malaria control pro-
grams is the ability to provide early diagnosis and treatment with
effective antimalarial drugs. Chloroquine (CQ) has been the most
commonly used drug for the treatment and prevention of malaria
since the 1940s; it is cheap, well tolerated, andwidely available.How-
ever, within a decade of its deployment, the first reports of CQ resis-
tancewere noted in Southeast Asia and SouthAmerica. By the 1980s,
CQ was no longer effective in much of these regions, and reports
began to emerge of declining efficacy inAfrica (2). It is estimated that
more than 80% of the world’s malaria is now resistant to CQ (3),
leading theWorld Health Organization (WHO) to recommend that
the use of CQ be restricted to non-falciparummalarias and the treat-
ment of falciparummalaria in a few specific areas only (4).
CQ resistance in P. falciparum is a multigenic process (5), the
main molecular determinant being mutations in the gene encod-
ing PfCRT (Plasmodium falciparum chloroquine resistance trans-
porter), a putative channel involved in enhanced CQ efflux from
the parasite’s digestive vacuole (DV) (6).
Several resistance reversal agents, also known as chemosensi-
tizers, have been identified and shown to inhibit CQ efflux in
CQ-resistant parasites (7). Many of these agents are licensed for
alternative medical conditions, such as antidepressants (desipra-
mine), antihistamines (chlorpheniramine), and calcium channel
blockers (verapamil). However, the doses required to achieve ad-
equate “reversal activity” in vivo can lead to poor tolerability and
adverse side effects for the patient (8).
One of the strategies to improve both pharmacokinetic and
pharmacodynamic properties of CQ resistance reversal agents is
to combine the reversal agent with CQ (8, 9). In 2006, Burgess et
al. reported innovative hybrid compounds, “reversed CQ” (RCQ)
molecules, combining a CQ-like moiety with a CQ resistance re-
versal agent closely related to imipramine (10). In vivo drug sus-
ceptibility testing showed that these molecules are potent in vitro
growth inhibitors of CQ-susceptible and CQ-resistant P. falcipa-
rum laboratory strains, with 50% inhibitory concentrations
(IC50s) in the low-nanomolar range (10). Subsequent studies in
animals have confirmed antimalarial efficacy with no overt signs
of toxicity (11). These compounds result in enhanced uptake and
accumulation in the parasite’s digestive vacuole of CQ-resistant
parasites and inhibition of hemozoin production in a manner
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analogous to, butmore potent than, that of CQ (11).However, the
efficacy of RCQs against P. falciparum field isolates has not been
reported, and there are no data on the efficacy of RCQcompounds
against P. vivax.
The aims of this study were to (i) investigate the ex vivo suscep-
tibility profiles of two RCQ compounds, PL69 and PL106 (Fig.
1A), against drug-resistant clinical isolates of P. falciparum and P.
vivax in Papua, Indonesia, (ii) to examine the stage-specific action
of these compounds, and (iii) to investigate cross-susceptibility
patterns with conventional antimalarials.
MATERIALS AND METHODS
Study area and field sample collection. The studies were conducted in
Timika, Papua Province, Indonesia, betweenMarch and October in 2011
and January and September in 2013. Patients presenting to the Rumah
Sakit Mitra Masyarakat (RSMM) Hospital were enrolled into the study if
diagnosed with amicroscopically confirmed P. falciparum or Plasmodium
vivaxmonoinfection and a parasitemia of between 2,000 and 80,000 par-
asites/l. Isolates of Plasmodium spp. were processed only if at least 70%
of asexual forms were at the ring stage (12). Patients treated with CQ in
the last 30 days or any other antimalarial treatments in the last 2 weeks
or hemoglobin levels below 5 g/dl were excluded. With written in-
formed consent, 5 ml of venous blood was collected by venipuncture
and processed immediately. Host white blood cells were removed us-
ing cellulose columns as previously described (13), and packed in-
fected red blood cells (iRBC) were used for the ex vivo drug suscepti-
bility assay.
Drug compounds and drug plate preparation. Each drug plate (96
wells) contained 11 serial concentrations (2-fold dilutions) in duplicate of
four antimalarials. The following antimalarial drugs were assayed: chlo-
roquine (CQ), amodiaquine (AQ), piperaquine (PIP), mefloquine
(MFQ), and artesunate (AS) (all provided by the WWARN QA/QC Ref-
erence Material Programme [14]), as well as the “reversed CQ” (RCQ)
compounds PL69 and PL106 (DesignMedix, Inc., Portland, OR) (Fig.
1A). Predosed drug plates were made by adding 25l of drug dilutions to
each well, followed by lyophilization and storage at 4°C. The following
maximum concentrations were used: 2,993 nM for CQ, 158 nM for AQ,
1,029 for PIP, 338 nM for MFQ, 49 nM for AS, and 295 nM and 349 nM
for the RCQ compounds PL69 and PL106, respectively.
FIG 1 (A) Chemical structure of “reversed chloroquine” (RCQ) compounds PL69 (compound 22 in reference 11) and PL106. (B) Ex vivo drug susceptibility
(median IC50s) to standard antimalarials and the RCQ compounds PL69 and PL106 in P. falciparum (closed symbols) and P. vivax (open symbols) clinical
isolates. Significance of P values was determined byWilcoxon rank sum test. (C and D) Ex vivo drug susceptibilities (median IC50s) for PL69 (C) and PL106 (D)
according to species tested and for paired ring-stage (closed symbols) versus trophozoite-stage (open symbols) parasites. Significance of P values was determined
by Wilcoxon rank sum test.
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Ex vivodrug susceptibility assay.Drug susceptibilities ofPlasmodium
isolates were measured using a modified schizont maturation assay as
described previously (15, 16). Drug susceptibility profiles were presented
as inhibition of parasite growth from the ring to schizont stage. Two
hundred microliters of a 2% hematocrit blood mediummixture (BMM),
consisting of RPMI 1640 medium supplemented with 10% AB human
serum (for P. falciparum) or McCoy’s 5A medium supplemented with
20% AB human serum (for P. vivax), was added to each well of the
predosed 96-well drug plates. The parasites were cultured in a candle jar at
37.0°C for 34 to 50 h. Incubation was stopped when more than 40% of
ring-stage parasites had reached themature schizont stage in the drug-free
control well.
The plates were harvested by preparing thick blood films from each
well of the plates. Thick blood filmswere stainedwith 5%Giemsa solution
for 25min and examinedmicroscopically. Differential counts of 200 asex-
ual parasites in the test slides were classified into ring stages, trophozoites,
and mature schizonts. To reduce parasite classification error and ease
parasite identification, only schizonts with at least 5 or more well-defined
chromatin dotswere classified as schizonts at harvest. Freemerozoites and
gametocytes were not included in the count. To determine the effect of
each antimalarial drug, the number of schizonts was determined for each
drug concentration and then normalized to that of the corresponding
drug-free control well.
To investigate the stage-specific drug susceptibility, Plasmodium iso-
lates with greater than 90% rings were set up (i) in culture in the presence
of drug directly for 24 h and after washing out of the drug for another 20
to 24 h and (ii) after culture in the absence of drug for 20 to 24 h to achieve
90% trophozoites that were then drug exposed for 20 to 24 h (17).
Data analysis. The raw dose-response data were analyzed using non-
linear regression analysis (WinNonLn 4.1; Pharsight Corporation), and
the IC50s were derived using an inhibitory sigmoid Emax model. Ex vivo
IC50 data were used only from predicted curves where the Emax (maxi-
mum effect) and E0 (minimum effect) were within 15% of 100 or 0,
respectively. Data analysis was performed using the STATA (version 13.1;
Stata Corp., College Station, TX) and GraphPad Prism (version 6) soft-
ware packages. The Mann-Whitney U test, Wilcoxon signed-rank test,
and Spearman’s rank correlation were used for nonparametric compari-
sons and correlations.
Ethical approval. Ethical approval for this project was obtained from
the Human Research Ethics Committee of the NT Department of Health
& Families and Menzies School of Health Research, Darwin, Australia
(HREC 2010-1396) and the Eijkman Institute Research Ethics Commis-
sion, Jakarta, Indonesia (EIREC-47) in September 2010.
RESULTS
Antimalarial susceptibility. Ex vivo drug susceptibility profiles
were attempted in 86 clinical isolates; baseline characteristics
of these isolates are presented in Table 1. Adequate growth for
harvest was achieved in 81% (33/41) of P. falciparum isolates
and 76% (34/45) of P. vivax isolates. The median IC50s for all
clinical isolates successfully cultured are shown in in Fig. 1B
and Table 2. PL69 IC50 estimates could not be derived for four
P. falciparum isolates (MIC, 295 nM) and one P. vivax isolate
(MIC,349 nM).
Drug susceptibility differed significantly between species, with
IC50s being higher in P. falciparum than in P. vivax for PIP (me-
dian IC50  27.3 nM versus 21.7 nM; P  0.012) and artesunate
(median IC50  4.6 nM versus 2.1 nM; P  0.001) but lower for
PL106 (median 26.6 versus 59.9 nM; P 0.021). In P. falcipa-
rum isolates, IC50s were significantly lower for PL69 and PL106
than for CQ. In P. vivax, IC50s for PL69 (median 19.0 nM; P
TABLE 1 Baseline characteristics of isolates for which ex vivo assays were accomplished
Baseline characteristic P. falciparum (n 41) P. vivax (n 45)
Isolates reaching harvest, no. (%) 33 (80.5) 34 (75.6)
Median delay from venipuncture to start of culture, min (range) 153 (85–280) 180 (100–330)
Median duration of assay, h (range) 46 (30–49) 48 (43–50)
Geometric mean parasitemia, no. of asexual parasites/l (95% CI)a 29,342 (19,286–44,639) 20,936 (14,293–30,666)
Median initial amt of parasites at ring stage, % (range) 100b 95 (71–99)
Mean schizont count at harvest, % (95% CI) 46 (16–76) 43 (25–70)
a CI, confidence interval.
b No range given. (All values were 100%.)
TABLE 2 Overall ex vivo susceptibility for each drug according to the species tested
Drug











(CQr) No. of assaysb
Median IC50, nM
(range)
Chloroquine 24.09 140.48 33 79.36 (10.92–158.66) 34 60.86 (8.96–334.55) 0.990
Amodiaquine 20.27 26.89 33 23.76 (4.56–71.38) 33 22.63 (8.80–49.16) 0.211
Piperaquine 31.72 47.21 33 27.30 (10.62–121.16) 34 21.69 (3.50–51.86) 0.013
Mefloquine 53.77 13.74 33 16.16 (3.23–53.29) 34 16.82 (4.83–61.48) 0.082
Artesunate 10.12 7.70 33 4.58 (0.83–25.90) 34 2.12 (0.88–13.54) 0.001
PL69 28.49 41.72 29 23.24 (3.18–85.54) 33 18.95 (1.70–114.87) 0.250
PL106 52.56 47.87 27 26.55 (2.18–228.26) 29 59.89 (10.45–248.41) 0.021
a Mean IC50s (derived from 3 independent experiments) were assessed by in vitro schizont maturation quantified by microscopy. CQ
s, chloroquine-sensitive laboratory strain; CQr,
chloroquine-resistant laboratory strain.
b Total number of assays with acceptable drug assay results.
c Significant difference in median drug IC50 between species.
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0.001) but not PL106 (median  59.9 nM) were significantly
lower than those for CQ (median 60.9 nM).
Stage-specific drug susceptibility. Stage-specific drug suscep-
tibility was investigated in 5 P. falciparum and 7 P. vivax isolates
(Table 3 and Fig. 1C and D). P. falciparum isolates assayed at
trophozoite stage had higher IC50s than with drug exposure at the
ring stage for PIP (median 128.2 nM versus 21.9 nM) but lower
IC50s for PL69 (median 50.7 nM versus 70.2 nM), although this
was of borderline significance (P 0.044 and 0.047, respectively).
In contrast, P. vivax isolates assayed at trophozoite stage had sig-
nificantly higher IC50s for CQ (median  778.2 nM versus 88.9
nM; P 0.003), AS (median 7.2 nM versus 1.9 nM; P 0.054),
PL69 (median 130.2 nMversus 17.6 nM; P 0.018), and PL106
(median 172.5 nM versus 91.3 nM; P 0.025).
Cross-susceptibility patterns. Spearman’s rank correlation
coefficients (rs) are presented in Table 4. PL69 showed signifi-
cantly positive correlations in both P. falciparum and P. vivax for
AQ (rs  0.512 and 0.457, respectively), PIP (rs  0.631 and
0.566), and MFQ (rs  0.480 and 0.556). However, the correla-
tions of PL69 were only significant with AS in P. falciparum (rs
0.446, P  0.015) and CQ in P. vivax (rs  0.727, P  0.001).
Contrasting correlation patterns between species were observed
for PL106 with significant positive correlations in P. falciparum
only apparent with PIP (rs 0.456, P 0.019). In P. vivax, PL106
was positively correlated with CQ (rs  0.830, P  0.001), AQ
(rs  0.505, P  0.005), and MFQ (rs  0.401, P  0.031) and
negatively correlated with AS (rs0.470, P 0.010).
DISCUSSION
This is the first report of the ex vivo drug susceptibilities of two
novel RCQ compounds, PL69 and PL106, against multidrug-re-
sistant clinical field isolates ofP. falciparum andP. vivax. The IC50s
of PL69 were 3-fold lower than those of CQ in both P. falciparum
and P. vivax and similar to those of AQ and PIP in both species.
While PL106 was also 3-fold more potent than CQ against P. fal-
ciparum, it was only moderately more potent than CQ in P. vivax.
However, 5 isolates (four of P. falciparum and one of P. vivax) had
elevated PL69 MICs, with the range of drug concentrations as-
sessed precluding derivation of reliable IC50s. The significance of
these findings warrants further molecular analysis.
Using our schizont maturation assay, the RCQ IC50s in the
laboratory strains FC27 and K1 ranged from 28.5 to 41.7 nM for
PL69 and 47.9 to 52.6 nM for PL106. These values are significantly
higher than the unpublished data derived using a SYBR green I
assay (range, 0.9 to 1.8 nM and 1.7 to 2.7 nM, respectively) (11).
This may reflect differences in the assay methodology. Previous
data for these RCQ compounds were derived by proliferation-
based growth inhibition assays of culture-adapted laboratory
strains in which in vitro growth was assessed by quantification of
DNA using a SYBR green I fluorescence-based assay. This meth-
odology generally produces similar results to radiotracer methods
such as [3H]hypoxanthine incorporation (18) but is known to
produce significantly lower IC50s than the field-based schizont
maturation assay used in the present study (19, 20).
Although the IC50s of the standard antimalarials were similar
between species, the IC50s of PL106 in P. vivax were almost 2-fold
higher than those observed in P. falciparum. However, since both
compounds (albeit PL106 to a lesser extent) have higher activity
than CQ in isolates of both species, this suggests an overall lower
CQ resistance reversal activity of PL106 than PL69 in P. vivax.
The two RCQ compounds showed notable differences in the
correlation patterns between and within the two Plasmodium spe-
cies (Table 4). Whereas statistically significant positive correla-
tions were found between PL69 and the quinoline-based antima-
larials AQ, PIP, and MFQ in both species, a strongly positive
correlationwith CQwas observed in P. vivax only (rs 0.727, P
0.001). The same was observed with PL106, which showed a
strong and significant positive correlation with CQ in P. vivax
(rs 0.830, P 0.001) but not in P. falciparum. This observation
TABLE 3 Ex vivo susceptibilities for paired isolates tested with 24 h of drug exposure at ring and trophozoite stage
Drug
P. falciparum P. vivax
na
Median IC50, nM (range)
Pb na
Median IC50, nM (range)
PbRings Trophozoites Rings Trophozoites
Chloroquine 5 107.87 (60.17–163.58) 142.71 (25.50–163.64) 0.855 8 88.87 (41.85–190.17) 778.18 (99.88–4,033.31) 0.003
Amodiaquine 5 16.23 (4.86–201.77) 17.96 (7.76–25.43) 0.570 8 21.61 (5.69–39.47) 53.22 (7.57–89.76) 0.062
Piperaquine 5 21.85 (7.78–33.28) 128.19 (13.80–359.25) 0.044 8 20.88 (9.76–69.60) 30.34 (18.08–205.52) 0.076
Mefloquine 5 15.26 (4.74–46.88) 17.26 (4.60–30.56) 0.570 8 17.87 (8.17–41.00) 37.06 (11.88–85.49) 0.062
Artesunate 5 2.10 (0.74–5.11) 3.87 (1.28–8.13) 0.584 8 1.91 (1.21–4.57) 7.20 (0.83–19.32) 0.054
PL69 5 90.39 (6.61–142.06) 23.55 (7.25–92.82) 0.465 7 17.59 (5.42–49.13) 130.22 (10.26–268.15) 0.018
PL106 5 70.17 (62.24–110.05) 50.67 (27.06–71.36) 0.047 6 91.25 (54.35–126.84) 172.48 (86.76–314.27) 0.025
a n, number of paired isolates.
b Comparison of drugs tested at ring and trophozoite stage, respectively (Wilcoxon rank sum test).
TABLE 4 Correlation of ex vivo antimalarial susceptibilities in
P. falciparum and P. vivax clinical field isolates
Antimalarial
combination
P. falciparum P. vivax
rs
a P dfb rs
a P dfb
PL69-CQ 0.097 0.618 29 0.727 0.001 33
PL69-AQ 0.512 0.005 29 0.457 0.008 33
PL69-PIP 0.631 0.001 29 0.566 0.001 33
PL69-MFQ 0.480 0.008 29 0.556 0.001 33
PL69-AS 0.446 0.015 29 0.124 0.492 33
PL106-CQ 0.113 0.582 26 0.830 0.001 29
PL106-AQ 0.036 0.862 26 0.505 0.005 29
PL106-PIP 0.456 0.019 26 0.332 0.079 29
PL106-MFQ 0.220 0.281 26 0.401 0.031 29
PL106-AS 0.108 0.601 26 0.470 0.010 29
PL106-PL69 0.472 0.023 23 0.694 0.001 29
a rs, Spearman rank correlation coefficient.
b df, degrees of freedom.
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most likely reflects the expected positive correlation between the
CQ moiety of the RCQ compounds and CQ due to their shared
modes of uptake, partition, and action; this action is abolished by
the potent reversal activity of these compounds in CQ-resistant P.
falciparum isolates. However, the fact that the same phenomenon
was not observed inP. vivax isolates indicates again that bothRCQ
compounds have greater CQ resistance reversal potential in P.
falciparum than in P. vivax. This is further corroborated by the
strong and significant correlation that was observed between PL69
and PL106 in P. vivax (rs 0.694, P 0.001) but not in P. falcip-
arum.
Our results confirm previous observations demonstrating the
marked stage specificity of chloroquine (12, 17) in P. vivax, with
trophozoites being almost completely resistant to CQ. IC50s for P.
vivax trophozoite stages were also higher for AS, PL69, and PL106
than for the ring stages of the same isolates, but this was not ap-
parent in P. falciparum (Table 3). Although P. vivax trophozoites
showed significantly higher median IC50s for PL69 (7-fold) and
PL106 (2-fold) than the ring stages, the values of the RCQ com-
pounds against P. vivax trophozoites were almost a log fold lower
than those of CQ, suggesting that some resistance reversal activity
was exerted against both stages.
Our results demonstrating ex vivo IC50s of the RCQ com-
pounds against CQ-resistantP. falciparumfield isolates in the low-
andmid-nanomolar ranges are in line with the data obtained with
P. falciparum laboratory strains. A previous study of P. vivax iso-
lates showedno significant difference betweenCQ IC50s of isolates
exposed to CQ alone compared to isolates exposed to CQ plus
verapamil (21). In the present study, RCQ IC50s in P. vivax were
lower than those of CQ,which suggests that the resistance reverser
moiety of the RCQ compounds does have an effect on CQ activity
in P. vivax isolates. The mechanisms of both CQ resistance and
CQ resistance reversal activity of various chemosensitizers have
been investigated in P. falciparum and revealed pfcrt to be a key
determinant of resistance and a target for chemosensitizers; how-
ever, both processes are likely to be mediated by multiple factors
(5, 22, 23). The knowledge of these processes in P. vivax is still
elusive. By using heterologous expression systems, Sa and col-
leagues have shown that the pfcrt orthologue pvcrt-o plays a role in
CQ accumulation and that increased accumulation could be re-
verted by verapamil (24). Our data demonstrating the CQ chemo-
sensitizing effect for the imipramine-like reversal agent in P. vivax
suggests that CQ resistance in this speciesmay also bemediated by
decreased drug accumulation; however, further investigations are
needed to better understand CQ pharmacokinetics and its genetic
determinants in P. vivax.
The RCQ compounds demonstrate significant enhancement
of ex vivo activity over CQ against CQ-sensitive and CQ-resistant
clinical isolates of bothP. falciparum andP. vivax andhighlight the
potential approach of reversal agents in antimalarial drug devel-
opment. Although the action of the RCQ compounds against P.
vivaxhas yet to be elucidated further, the current variation of RCQ
compounds between P. falciparum and P. vivax supports a grow-
ing body of work suggesting that CQ uptake and metabolism, as
well as CQ resistance mechanisms, in these two species may be
different (25).
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